|Bid||15.26 x 900|
|Ask||15.30 x 800|
|Day's Range||15.02 - 15.42|
|52 Week Range||5.14 - 16.59|
|Beta (3Y Monthly)||2.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.88|
Massachusetts is home to 36 of the 500 companies making this year’s ranking, with three local firms making the top 100 — including the No. 2 spot.
NEW YORK, Nov. 5, 2019 /PRNewswire/ -- Royalty Pharma announced today that it has agreed to pay $330 million to purchase Eisai Co., Ltd.'s royalties on future worldwide sales of tazemetostat, Epizyme Inc.'s (EPZM) lead investigational agent, outside of Japan, and made an equity investment in Epizyme of $100 million, with options to invest up to an additional $100 million in Epizyme common stock. In addition, investment funds managed by Pharmakon Advisors agreed to provide $70 million in senior-secured loans with the possibility to fund up to $370 million over time.
$100 Million Upfront Investment by Royalty Pharma with Up to $100 Million in Future Equity
Epizyme (EPZM) delivered earnings and revenue surprises of 25.93% and 3.91%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Pre-NDA Meeting Supports Registration Strategy for Tazemetostat for Follicular Lymphoma Patients with and without EZH2 Activating Mutations and Planned NDA Submission in December 2
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Epizyme (EPZM) aims at developing its lead pipeline candidate, tazemetostat, which is under FDA review with an action date of Jan 23, 2020.
Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetostat.
Epizyme (EPZM) delivered earnings and revenue surprises of 0.00% and 424.45%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Epizyme (EPZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.